B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
News / Global & Trade
AdvaMed Statement on FDA-USAID India Regulatory Session
April 16, 2024
AdvaMed, the Medtech Association, released the following statement thanking the FDA Center for Radiological Health (CDRH) for recently hosting an event in New Delhi to discuss regulatory policies and best practices for ensuring medical technology reaches patients. The event, called “Minds to Markets: Regulatory Considerations in Med-Tech,” advances US-India cooperation on medtech supply chain through greater regulatory alignment.
Resource / Regulatory Affairs
Successful Market Access of SaMD & MDSW: Decoding the Confusion in MedTech Software Development
April 12, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.
Resource / Regulatory Affairs
PFAS in Medtech
March 8, 2024
News / Global & Trade
AdvaMed Statement on the World Trade Organization Ministerial Conference
March 1, 2024
AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker regarding the conclusion of the World Trade Organization Ministerial conference in Abu Dhabi.
News / Ethylene Oxide / Regulatory Affairs
AdvaMed Anticipates EtO Sterilization Rule, Voices Concern About Impact on Patient Care
February 27, 2024
By Friday, March 1, the Environmental Protection Agency is expected to finalize its regulation for the ethylene oxide (EtO) sterilization of 20 billion, or half, of all medical devices in the United States each year. AdvaMed President and CEO Scott Whitaker released the following statement:
Resource / Regulatory Affairs
Artificial Intelligence in Medtech
February 21, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.
Resource / Regulatory Affairs
Artificial Intelligence in Medical Technology Myths and Facts
February 21, 2024
Outlining the facts and dispelling myths will inform policymaking to avoid overlap with current regulations and preserve the broad capacity of innovation to help patients.
Resource / Regulatory Affairs
Principles for Artificial Intelligence in Medical Technology
February 21, 2024
This document provides the medical device industry’s foundational principles for artificial intelligence in medical technology. These principles will guide further innovations, policymaking, and regulations in AI-enabled medical technology.